[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3353 High Progression-Free Survival At 10 Years After Tandem Autologous/Nonmyeloablative Allogeneic Transplants For Multiple Myeloma In a Cohort Of 93 Patients: Impact Of Disease Remission Status At Transplant and Chronic Graft-Versus-Host Disease

Program: Oral and Poster Abstracts
Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Poster II
Sunday, December 8, 2013, 6:30 PM-8:30 PM
Hall G (Ernest N. Morial Convention Center)

Imran Ahmad, MD, MSc1, Sandra Cohen, MD2, Silvy Lachance, MD2, Guy Sauvageau, MD, PhD2, Thomas Kiss, MD2, Lambert Busque, MD3, Denis-Claude Roy, MD2, Jean-Sebastien Delisle, MD, PhD4, Lea Bernard, MD2, Richard LeBlanc, MD2* and Jean Roy, MD5

1Division of Hematology and Medical Oncology, Department of Medicine, Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, QC, Canada
2Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal, QC, Canada
3Department of Hematology, Hopital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC, Canada
4Hôpital Maisonneuve-Rosemont Research Center (CR-HMR), Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC, Canada
5Department of Hematology and Cellular Therapy Laboratory, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, QC, Canada


Despite improved survival with new molecules, allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the only curative option for multiple myeloma (MM). Myeloablation with autologous HSCT (autoHSCT) followed by nonmyeloablative (NMA) alloHSCT has reduced the high nonrelapse mortality (NRM) rates associated with myeloablative alloHSCT, but randomized trials comparing NMA alloHSCT with standard therapy have yielded conflicting results. Factors affecting long-term outcomes have not been clearly defined. We sought to identify factors associated with outcomes in a large single-center cohort of 93 tandem transplant recipients.


We conducted a prospective phase II trial in Durie-Salmon (DS) stage II/III newly diagnosed MM patients <65 years with a 6/6 sibling donor, characterized by outpatient alloHSCT and complete immunosuppression withdrawal by day +100. Following induction therapy, patients received autoHSCT followed 3 months later by an outpatient NMA alloHSCT. Conditioning regimen consisted of fludarabine (30 mg/m2 x 5 days) and cyclophosphamide (300 mg/m2 x 5 days), followed by donor G-CSF mobilized stem cells (target dose: 4 x 10^6 CD34+/kg). GVHD prophylaxis included tacrolimus (day -10 to +50, taper by +100) and mycophenolate mofetil 1000 mg BID (day +1 to +50). Probabilities of overall and progression-free survival (OS and PFS), relapse, NRM and graft-versus-host disease (GVHD) incidences were estimated taking competing risks into account when appropriate. Regression analysis using Cox and Fine & Gray models were used to determine factors influencing outcomes. Severity of chronic GVHD was assessed by the proportion of alive patients on systemic immunosuppression.


From 2001 to 2010, 93 patients received tandem HSCT from a matched sibling donor; median age was 52 years (range 39-64) and DS stage III present in 76%. All but 6 patients received a single line of induction therapy. Median time from diagnosis to autoHSCT and from auto- to alloHSCT were 7 (range 3-57) and 4 (range 2-13) months, respectively. At least partial remission (PR) status was obtained in 84% patients before tandem HSCT. After a median follow-up of 7 years, cumulative incidences of grade II-IV acute and extensive chronic GVHD were 9% (95%CI: 4-15) and 85% (75-91) respectively. Cumulative incidences of NRM and progression were 10% (95%CI: 3-22) and 47% (37-58; Fig. 1). Probability of 10-year OS and PFS were 64% (50-74; Fig. 2) and 44% (31-56; Fig. 1) respectively. In multivariate analysis, at least stable disease (SD) status before alloHSCT was a significant protective factor for progression incidence and PFS (respectively, HR 0.18, CI: 0.05-0.64, and HR 0.12, CI: 0.04-0.36).  Extensive chronic GVHD as time-dependent variable was also protective for PFS (HR 0.39, CI: 0.19-0.80). The most significant protective factor for OS was at least SD status before alloHSCT (HR 0.15, CI: 0.04-0.56). The association between chronic GVHD and OS did not reach statistical significance. In survivors, the probability of being on systemic immunosuppressive treatment for GVHD was 39% (CI: 27-52) at 5 years and 15% (CI: 4-42) at 10 years.


We report a very high PFS of 44% at 10 years in a large cohort of 93 NMA alloHSCT recipients. Despite the high incidence of chronic GVHD, we observed a low NRM of 10% and an acceptable prevalence of immunosuppressive therapy of 15% at 10 years. Chronic extensive GVHD and achievement of disease control before HSCT were both associated with better PFS. Patients with progressive disease do not seem to benefit from NMA alloHSCT and efforts to reduce chronic GVHD could increase the risk of relapse. Agents active against both MM and GVHD might allow better long-term remission while reducing the burden of GVHD.

Figure 1 (left) shows stacked cumulative incidence of transplant failure by either progression (light grey) or nonrelapse mortality (dark grey). Figure 2 (right) shows the probability of overall survival with 95% confidence interval.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH